title: Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.
authors.forename: M
authors.initials: M
authors.lastname: Inami
authors.forename: K
authors.initials: K
authors.lastname: Inokuchi
authors.forename: M
authors.initials: M
authors.lastname: Okabe
authors.forename: F
authors.initials: F
authors.lastname: Kosaka
authors.forename: Y
authors.initials: Y
authors.lastname: Mitamura
authors.forename: H
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: K
authors.initials: K
authors.lastname: Dan
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D053614:Janus Kinase 2 / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use*; D011086:Polycythemia / Q000209:etiology*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C507924:JAK2 protein, human; D053614:Janus Kinase 2